FY2024 EPS Estimates for XFOR Reduced by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for shares of X4 Pharmaceuticals in a note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($0.67) per share for the year, down from their prior estimate of ($0.62). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at $0.42 EPS.

A number of other brokerages have also commented on XFOR. Stifel Nicolaus dropped their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright dropped their price objective on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 9.4 %

Shares of XFOR stock opened at $0.64 on Thursday. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The firm has a market capitalization of $108.52 million, a PE ratio of -7.07 and a beta of 0.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The stock’s 50-day simple moving average is $0.55 and its 200-day simple moving average is $0.62.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Barclays PLC increased its stake in shares of X4 Pharmaceuticals by 196.0% in the 3rd quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after purchasing an additional 183,861 shares in the last quarter. XTX Topco Ltd grew its holdings in X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after purchasing an additional 46,397 shares during the period. Jane Street Group LLC increased its position in shares of X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after buying an additional 126,296 shares in the last quarter. State Street Corp raised its stake in shares of X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in shares of X4 Pharmaceuticals by 15.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after buying an additional 81,968 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.